Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. reports news about its consumer telehealth platform, which connects customers with providers and offers treatment options across areas such as sexual health, hair loss, skin care, mental health and weight loss. Company updates commonly cover prescription access, FDA-approved GLP-1 weight loss medications, platform memberships, subscriber benefits and health-and-wellness partner programs.
Recurring developments also include operating and financial results, conference participation, board and executive appointments, shareholder voting matters, governance updates and clinical or regulatory disclosures tied to products available through the Hims and Hers platform.
Hims & Hers (NYSE:HIMS) appointed Dr. Anant Vinjamoori as Chief Medical Officer of the Hims brand.
He will guide clinical strategy across sexual, hormone, dermatology, weight loss, and mental health, plus longevity and peptide therapy, joining a medical leadership team with over 100 years of combined experience.
Hims & Hers (HIMS) completed its acquisition of Eucalyptus, parent of weight management brand Juniper, strengthening its Canadian presence after launching in 2025 and introducing generic semaglutide.
The combined platform aims to expand personalised, preventive care across weight management, sexual health and hair loss for Canadian adults.
Hims & Hers (NYSE:HIMS) has completed its acquisition of Eucalyptus, parent of Juniper, to expand clinically backed, personalised weight management care in Germany. Juniper’s program, launched in March 2023, will gain Hims & Hers technology, data, and clinical infrastructure while maintaining local licensed providers and uninterrupted care.
Hims & Hers (NYSE:HIMS) has completed its acquisition of Eucalyptus, parent of Juniper, formally entering the Japanese market.
The deal brings Hims & Hers’ technology, data, and clinical infrastructure to Juniper’s evidence-based weight management platform, supporting local customers through Japanese providers while maintaining continuity of care and expanding resources.
Hims & Hers (NYSE:HIMS) has completed its acquisition of Eucalyptus, which the company says advances its position as the world’s largest consumer health platform. The deal expands its leadership across Australia, Canada, Germany, Japan, the UK and strengthens presence in the US and Europe.
According to Hims & Hers, the combined platform can now reach hundreds of millions of people across four continents, supported by local clinical expertise and data-driven care. The company reiterated confidence in its 2030 long-term targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.
Hims & Hers (NYSE:HIMS) expanded its Hims & Hers Benefits program, adding eight new partners across nutrition, fitness, women’s health, metabolic monitoring, and connected wellness. The lineup now includes iFIT, Ladder, MyFitnessPal, HelloFresh, Factor, Flo Health, Natural Cycles, PVOLVE Studios, Dexcom’s Stelo, Prenuvo, and Eight Sleep.
The program now offers 10 ways for active subscribers to support whole-body health, including discounted subscriptions, free trial periods, and meal offers. According to Hims & Hers, it does not profit from these benefits and passes 100% of negotiated value directly to active subscribers, who can access them immediately.
Hims & Hers (NYSE:HIMS) launched access to generic semaglutide for eligible customers in Canada, offering GLP-1-based personalised treatment plans starting at $149/month CAD. Plans combine medication, unlimited Care Team support, and evidence-informed guidance on nutrition, movement, and sleep, delivered by Canadian healthcare providers.
Generic semaglutide is authorized by Health Canada for Type 2 diabetes and may be prescribed off-label for weight management at a provider’s discretion.
Hims & Hers (NYSE:HIMS) launched access to generic semaglutide in Canada, its first international generic GLP-1 offering. Personalized weight-management treatment plans start at $149 CAD/month, aiming to expand access to affordable GLP-1 therapies.
Canadian patients receive care from local providers with ongoing support and lifestyle resources.
Hims & Hers (NYSE:HIMS) priced an upsized $350 million 0.00% convertible senior notes offering due 2032 to qualified institutional buyers under Rule 144A. The notes, upsized from $300 million, carry an initial conversion price of $29.53, a 32.5% premium to the May 18, 2026 share price.
Estimated net proceeds of $338.5–$389.5 million will support international expansion, the proposed Eucalyptus acquisition, technology and fulfillment investments, and AI platform scaling. About $32 million will fund capped call transactions, initially capped at $50.15 per share to help limit dilution on conversion.
Hims & Hers Health (NYSE:HIMS) plans a private offering of $300 million convertible senior notes due June 1, 2032, with an option for an additional $45 million.
According to Hims & Hers, proceeds will support international expansion, the proposed Eucalyptus acquisition, AI and infrastructure investment, capped call costs, and general corporate purposes.